A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose Combinations (NCT06101134)
A Phase 2 Open-label, Two-cohort Study to Evaluate Patient Preference for Nivolumab + Relatlimab Fixed-dose Combination Subcutaneous Versus Nivolumab + Relatlimab Fixed-dose Combination Intravenous and Nivolumab Subcutaneous Versus Nivolumab Intravenous in Participants With Melanoma
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to assess the patient's preference for nivolumab subcutaneous (SC) or nivolumab + relatlimab fixed-dose combination (FDC) SC and provide patient experience data by route of administration. This study will also generate safety data which will further characterize the safety profile of patients switching the route of administration from intravenous (IV) to SC.
Who can join: Review the eligibility criteria below.
Location: Local Institution - 0007 — Anchorage, Alaska
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (31 Sites)
Showing the first 25 of 31 sites.
- Local Institution - 0007 — Anchorage, Alaska
- Local Institution - 0013 — Phoenix, Arizona
- Local Institution - 0010 — San Francisco, California
- Local Institution - 0034 — Atlanta, Georgia
- Local Institution - 0032 — Edgewood, Kentucky
- Local Institution - 0028 — Albuquerque, New Mexico
- Local Institution - 0037 — Edmonds, Washington
- Local Institution - 0036 — Issaquah, Washington
- Local Institution - 0030 — Seattle, Washington
- Local Institution - 0015 — Las Condes, Santiago Metropolitan
- Local Institution - 0005 — Concepción,
- Local Institution - 0019 — Thessaloniki, B
- Local Institution - 0014 — Athens, I
- Local Institution - 0029 — Marousi, I
- Local Institution - 0023 — Holargos, Athens,
- Local Institution - 0008 — Piraeus,
- Local Institution - 0033 — Thessaloniki,
- Local Institution - 0017 — Bergamo, BG
- Local Institution - 0035 — Meldola, FC
- Local Institution - 0018 — Milan, MI
- Local Institution - 0012 — Padova, PD
- Local Institution - 0021 — Roma, RM
- Local Institution - 0004 — Torino, TO
- Local Institution - 0026 — Naples,
- Local Institution - 0011 — Barcelona, B
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Melanoma
- Randomized Study Comparing Two Dosing Schedules for Hypofractionated Image-Guided Radiation Therapy — San Francisco, California
- An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942) — Tucson, Arizona
- Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation. — CABA, Buenos Aires
- Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients — Santa Monica, California
- NeoVax + CDX-301 and Nivolumab or Pembrolizumab in Melanoma — Boston, Massachusetts
- A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma — Orlando, Florida
Explore by condition: All Melanoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.